Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Clinical research in CLL/SLL centers on pirtobrutinib and related Bruton’s tyrosine kinase-targeted approaches for patients with previously treated disease, untreated disease, and BTK-inhibitor exposure.
- Progression-free survival
- Overall response rate
- Combination therapy with venetoclax and rituximab
Studies also include comparisons with bendamustine plus rituximab and idelalisib-based regimens in relapsed or refractory settings.
Mantle Cell Lymphoma and Non-Hodgkin Lymphoma
The sponsor funds trials in mantle cell lymphoma and broader non-Hodgkin lymphoma, with attention to patients whose disease has progressed after prior treatment and those needing alternative BTK-directed options.
- Pirtobrutinib monotherapy
- Objective response rate
- Comparative treatment against covalent BTK inhibitors
Research activity includes evaluation of treatment options for CLL/SLL and MCL populations with prior exposure to targeted agents.
RET-Altered Solid Tumors
Trials in locally advanced and metastatic solid tumors focus on cancers with a RET gene alteration identified in tumor tissue or blood, using selpercatinib as a central investigational therapy.
- RET inhibition
- Objective response rate
- Progression-free survival
These studies extend across adult and adolescent patients with advanced RET-driven malignancies.
Pediatric Oncology and Primary Central Nervous System Tumors
Research in pediatric cancer includes children and adolescents with advanced RET-altered solid tumors and primary central nervous system tumors, reflecting interest in molecularly defined disease across younger populations.
- Selpercatinib
- RET-altered malignancies
- Central nervous system tumors
The portfolio addresses tumor types where targeted therapy may be relevant in the pediatric setting.
